Hologic
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
ASCO Guideline Update Expands, Clarifies Use of Breast Cancer Adjuvant Treatment Test
The update incorporates recent evidence on test performance in different categories of patients based on age, menopausal status, and lymph node positivity.
Medicare Expands Coverage for Hologic's Biotheranostics Breast Cancer Test
The firm said that the expanded coverage provides more women with access to a test that helps determine whether extended endocrine therapy is appropriate.
In Brief This Week: Kura Oncology, Innovent Biologics, Iaso Biotherapeutics, Invitae, Hologic
News items for the week of Feb. 22, 2021.
In Brief This Week: Janssen, Hologic, Guardant Health, More
News items for the week of Feb. 1, 2021.